Last year was a strong year for L1’s healthcare arm, with tremendous growth in its two original assets in the US and – together with our transaction partner Blantyre Capital – the acquisition of two new assets in Europe. L1 Health has now
committed over $1b to a diversified portfolio across Biotech, Animal Health, Pharma
Services and Consumer Health.

Please read our full Annual Review for more details on our progress over 2021.